Amicus Therapeutics, Inc. (FOLD) CEO Sells $642,568.93 in Stock
Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley sold 47,213 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $13.61, for a total value of $642,568.93. Following the transaction, the chief executive officer now directly owns 375,214 shares in the company, valued at approximately $5,106,662.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Shares of Amicus Therapeutics, Inc. (NASDAQ FOLD) traded up $0.03 during trading on Wednesday, reaching $12.54. The company’s stock had a trading volume of 1,823,624 shares, compared to its average volume of 3,179,943. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. Amicus Therapeutics, Inc. has a 52-week low of $4.41 and a 52-week high of $16.60.
Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The business had revenue of $10.90 million for the quarter, compared to analyst estimates of $9.02 million. Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The business’s revenue was up 419.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.33) earnings per share. sell-side analysts forecast that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current year.
A number of brokerages have weighed in on FOLD. Leerink Swann reissued a “buy” rating and set a $20.00 price target (up previously from $17.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Robert W. Baird reaffirmed an “outperform” rating and issued a $16.00 target price on shares of Amicus Therapeutics in a research report on Monday, September 25th. J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $15.00 target price (up previously from $13.00) on shares of Amicus Therapeutics in a research report on Wednesday, August 9th. Cowen reaffirmed a “buy” rating and issued a $16.00 target price on shares of Amicus Therapeutics in a research report on Monday, August 14th. Finally, Zacks Investment Research downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 12th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Amicus Therapeutics currently has a consensus rating of “Buy” and an average target price of $17.81.
Hedge funds have recently added to or reduced their stakes in the company. Strs Ohio bought a new position in shares of Amicus Therapeutics during the 3rd quarter worth about $102,000. Teacher Retirement System of Texas boosted its position in shares of Amicus Therapeutics by 1.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 169 shares in the last quarter. Tudor Investment Corp ET AL bought a new position in shares of Amicus Therapeutics during the 2nd quarter worth about $124,000. Aperio Group LLC boosted its position in shares of Amicus Therapeutics by 13.5% during the 2nd quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 1,663 shares in the last quarter. Finally, Zacks Investment Management bought a new position in shares of Amicus Therapeutics during the 2nd quarter worth about $145,000.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.